BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16171088)

  • 21. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Doi T; Ohtsu A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
    [No Abstract]   [Full Text] [Related]  

  • 24. Second-line treatment of patients with metastatic colorectal cancer.
    Rougier P; Lepere C
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S48-54. PubMed ID: 16399432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 26. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatments for colorectal cancer.
    FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
    [No Abstract]   [Full Text] [Related]  

  • 29. Two new drugs for colon cancer.
    Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
    [No Abstract]   [Full Text] [Related]  

  • 30. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New therapy options in colorectal carcinoma].
    Folprecht G; Köhne CH
    Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined-modality therapy for rectal cancer: future prospects.
    Czito BG; Willett CG; Bendell JC
    Clin Colorectal Cancer; 2007 Sep; 6(9):625-33. PubMed ID: 17945034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic colorectal cancer: is there one standard approach?
    Saltz LB
    Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab in colorectal cancer.
    Sonpavde G
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
    [No Abstract]   [Full Text] [Related]  

  • 38. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
    Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
    [No Abstract]   [Full Text] [Related]  

  • 39. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
    Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
    Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.